Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress

Journal of Ethnopharmacology

Volumn 176, Issue , 2015, Pages 499-507

  Jiang, Youzhao ^a   Chen, Liu ^a   Wang, Hui ^a   Narisi, Bao ^b   Chen, Bing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

Fatty acid oxidation; HepG2 cells; Li Gan Shi Liu Ba Wei San; Non alcoholic fatty liver disease; Oxidative stress

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LI GAN SHI LIU BA WEI SAN; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; I KAPPA B; I KAPPA B KINASE ALPHA; LI-GAN-SHI-LIU-BA-WEI-SAN; NFKBIA PROTEIN, HUMAN; NFKBIA PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FATTY ACID OXIDATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIPID OXIDATION; MONGOLIAN MEDICINE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ANIMAL; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; LIPID METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION REDUCTION REACTION; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DRUGS, CHINESE HERBAL; HEP G2 CELLS; HUMANS; I-KAPPA B PROTEINS; LIPID METABOLISM; LIVER; MALONDIALDEHYDE; NF-KAPPAB INHIBITOR ALPHA; NITRIC OXIDE SYNTHASE TYPE II; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PPAR ALPHA; PPAR-BETA; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 84948662779     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.11.019     Document Type: Article

References (21)

1. W. Wang, Y. He, P. Lin, Y. Li, R. Sun, W. Gu, J. Yu, and R. Zhao In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism J. Ethnopharmacol. 153 2014 763 770
2. E.S. Choi, M.K. Kim, M.K. Song, J.M. Kim, E.S. Kim, W.J. Chung, K.S. Park, K.B. Cho, J.S. Hwang, and B.K. Jang Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees PLoS One 9 2014 e110680
3. R.J. Wong, M. Aguilar, R. Cheung, R.B. Perumpail, S.A. Harrison, Z.M. Younossi, and A. Ahmed Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 148 2015 547 555
4. S. Stojsavljevic, P.M. Gomercic, J.L. Virovic, D.L. Smircic, and M. Duvnjak Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease World J. Gastroenterol. 20 2014 18070 18091
5. J. Yin, Y. Luo, H. Deng, S. Qin, W. Tang, L. Zeng, and B. Zhou Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARalpha pathways in L02 cells and HepG2 cells J. Ethnopharmacol. 154 2014 229 239
6. Sh.X. Wu Cheng Fangxuan of Mongolian Medicine 1984 People Press of Inner Monggol China
7. Q.Y. Bai Mongolian Medicine of Chinese Medical Encyclopedia 1986 Science and Technology Press of Nei Monggol China
8. X.Y. Shi Medical Laboratory Animal Science 1987 Science and Technology Press of ShaanXi China
9. T. Kilic, H. Parlakpinar, E. Taslidere, S. Yildiz, A. Polat, N. Vardi, C. Colak, and H. Ermis Protective and therapeutic effect of apocynin on bleomycin-induced lung fibrosis in rats Inflammation 38 2015 1166 1180
10. Y.W. Cao, Y. Jiang, D.Y. Zhang, M. Wang, W.S. Chen, H. Su, Y.T. Wang, and J.B. Wan Protective effects of Penthorum chinense Pursh against chronic ethanol-induced liver injury in mice J. Ethnopharmacol. 161 2015 92 98
11. R. Radi Peroxynitrite, a stealthy biological oxidant J. Biol. Chem. 288 2013 26464 26472
12. I.M. Cojocaru, M. Cojocaru, V. Sapira, and A. Ionescu Evaluation of oxidative stress in patients with acute ischemic stroke Rom. J. Intern Med. 51 2013 97 106
13. V.G. Giby, and T.A. Ajith Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease World J. Hepatol. 6 2014 570 579
14. T.B. Zhou, G.P. Drummen, Z.P. Jiang, Y.B. Long, and Y.H. Qin Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases J. Recept. Signal Transduct. Res. 33 2013 349 352
15. J.G. Neels, and P.A. Grimaldi Physiological functions of peroxisome proliferator-activated receptor beta Physiol. Rev. 94 2014 795 858
16. M.T. Nakamura, B.E. Yudell, and J.J. Loor Regulation of energy metabolism by long-chain fatty acids Prog. Lipid Res. 53 2014 124 144
17. S. Purushothaman, M.M. Sathik, and R.R. Nair Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart J. Cardiovasc. Pharmacol. 58 2011 254 262
18. J. Huang, Y. Jia, T. Fu, N. Viswakarma, L. Bai, M.S. Rao, Y. Zhu, J. Borensztajn, and J.K. Reddy Sustained activation of PPARalpha by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice FASEB J. 26 2012 628 638
19. C.L. Chen, C.F. Lin, S.W. Wan, L.S. Wei, M.C. Chen, T.M. Yeh, H.S. Liu, R. Anderson, and Y.S. Lin Anti-dengue virus nonstructural protein 1 antibodies cause NO-mediated endothelial cell apoptosis via ceramide-regulated glycogen synthase kinase-3beta and NF-kappaB activation J. Immunol. 191 2013 1744 1752
20. C.Y. Cheng, H.L. Hsieh, C.C. Sun, C.C. Lin, S.F. Luo, and C.M. Yang IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells J. Cell. Physiol. 219 2009 183 193
21. L. Rochette, J. Lorin, M. Zeller, J.C. Guilland, L. Lorgis, Y. Cottin, and C. Vergely Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol. Ther. 140 2013 239 257